Dear All, I previously wrote (link) about the first of Jason Gale‘s 4-part podcast series on AMR. The whole series is now out and definitely worth your time. Each podcast is about 30 minutes long … please set aside a bit of time to listen to all four! Here they are: #1: In a detailed look at
Dear All, If you’re going to be in New York City on 23 Sep for the UN General Assembly, you are invited to join U.S. Health and Human Services Secretary, Alex Azar, experts from the U.S. Centers for Disease Control and Prevention, and hundreds of organizational and global leaders at an evening celebrating global AMR
Dear All, Clear analyses by our colleagues in the science-focused media are invaluable ways to educate both ourselves and others: we learn new viewpoints while our non-technical friends and colleagues learn what keeps us up at night. On this note, we have two recently released 30-minute podcasts that are very much worth hearing and sharing.
Dear All, Committing serial email this afternoon… First, the note I just sent on FMT for Clostridium difficile (link) prompted comments that the organism is now called Clostridioides difficile. This name change slipped past me, I’ll admit! But it does seem a settled change … see this helpful editorial from May 2019 in Lancet ID for a summary of how the new
Dear All, On 4 Nov 2019 at their White Oak Campus, FDA will hold a public hearing from 9a-4p on fecal microbiota transplantation (FMT) to treat Clostridium difficile infections that are not response to standard therapies. Go here for the online FR notice and here for the .pdf version. The background on this topic goes back several years and is well
Dear All, Two time-limited opportunities have been announced in the past few days. First, the Novo REPAIR Impact Fund has opened its 2019 US-Canada-focused investment round. Non-confidential proposals are due by 11 Oct … go here for details. Note that you need to dig all the way to the bottom of the web page to find the information.
Dear All, First, Alan Carr’s Sep 2019 Antibiotic and Antifungal Update (link) is, as usual, required reading (see also this prior blog). Key highlights: He provides an updated by-month sales report from Jan 2016 through Jul 2019 of all products approved since 2009. Sadly, it remains the case that only 4 drugs have sold more than $100m in the
Dear All, Addendum: This project ultimately led to publishing in May 2020 of a set of TPPs for enteric fever, gonorrhea, neonatal sepsis, and urinary tract infections as guides for developers. You can find those TPPs at https://www.who.int/publications/i/item/9789240003897. WHO has developed a set of draft TPPs (target product profiles) for needed new antibiotics. As part of the
Dear All, Two mid-week notes: First (and huge!), India’s Ministry of Health issued a notification last week prohibiting the “manufacture, sale and distribution of the drug colistin and its formulations for food-producing animals, poultry, aqua farming and animal feed supplements” because such use is “likely to involve risk to human beings.” You can find this on multiple
Dear All, Your vote counts! The UN’s Inter-Agency and Expert Group on Sustainable Development Goal Indicators (IAEG-SDGs) is conducting an open consultation on proposals it is considering including in the 2020 Comprehensive Review and is seeking the global community’s comments on these proposals (link to summary web page). The 17 SDGs were adopted in 2015 and are really driving